Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy
Top Cited Papers
- 1 March 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7), 734-747
- https://doi.org/10.1200/jco.20.02015
Abstract
Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online eHealth system for patients to self-report symptoms during cancer treatment. It provides automated severity-dependent patient advice guiding self-management or medical contact and displays the reports in electronic patient records. This trial evaluated the impact of eRAPID on symptom control, healthcare use, patient self-efficacy, and quality of life (QOL) in a patient population treated predominantly with curative intent. Patients with colorectal, breast, or gynecological cancers commencing chemotherapy were randomly assigned to usual care (UC) or the addition of eRAPID (weekly online symptom reporting for 18 weeks). Primary outcome was symptom control (Functional Assessment of Cancer Therapy-General, Physical Well-Being subscale [FACT-PWB]) assessed at 6, 12, and 18 weeks. Secondary outcomes were processes of care (admissions or chemotherapy delivery), patient self-efficacy, and global quality of life (Functional Assessment of Cancer Therapy–General, EQ5D-VAS, and EORTC QLQ-C30 summary score). Multivariable mixed-effects repeated-measures models were used for analyses. Trial registration: ISRCTN88520246. Participants were 508 consenting patients (73.6% of 690 eligible) and 55 health professionals. eRAPID compared to UC showed improved physical well-being at 6 (P = .028) and 12 (P = .039) weeks and no difference at 18 weeks (primary end point) (P = .69). Fewer eRAPID patients (47%) had clinically meaningful physical well-being deterioration than UC (56%) at 12 weeks. Subgroup analysis found benefit in the nonmetastatic group at 6 weeks (P = .0426), but not in metastatic disease. There were no differences for admissions or chemotherapy delivery. At 18 weeks, patients using eRAPID reported better self-efficacy (P = .007) and better health on EQ5D-VAS (P = .009). Average patient compliance with weekly symptom reporting was 64.7%. Patient adherence was associated with clinician's data use and improved FACT-PWB at 12 weeks. Real-time monitoring with electronic patient-reported outcomes improved physical well-being (6 and 12 weeks) and self-efficacy (18 weeks) in a patient population predominantly treated with curative intent, without increasing hospital workload.Keywords
This publication has 41 references indexed in Scilit:
- A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic settingBMC Health Services Research, 2013
- Emergency department visits for symptoms experienced by oncology patients: a systematic reviewSupportive Care in Cancer, 2012
- The use of count data models in biomedical informatics evaluation researchJournal of the American Medical Informatics Association, 2012
- Interpreting patient-reported outcome results: US FDA guidance and emerging methodsExpert Review of Pharmacoeconomics & Outcomes Research, 2011
- Assessing self‐efficacy for coping with cancer: development and psychometric analysis of the brief version of the Cancer Behavior Inventory (CBI‐B)Psycho‐Oncology, 2011
- Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicitySupportive Care in Cancer, 2008
- Development and Testing of a Short Form of the Patient Activation MeasureHealth Services Research, 2005
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993